SEOUL: Samsung BioLogics Co Ltd, a contract manufacturer of biotech drugs for global pharmaceutical firms, said its initial public offering is expected to raise as much as US$2bil in what is set to be South Korea's third-largest IPO.
The listing is aimed at helping fund an ambitious expansion in production capacity to make it the world's largest contract manufacturer.
Join our Telegram channel to get our Evening Alerts and breaking news highlights
